Aktienanalyse zu Tvardi Therapeutics Inc (TVRD)TVRDTvardi Therapeutics Inc

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. It operates in the Healthcare sector.

While Tvardi Therapeutics has shown some positive developments, such as a recent upgrade to Overweight with a price target of $13, the current price of $1.82 reflects significant risks. The company reported a 93.85% decline over the past year and has a negative net income of -$6,457,000 for Q2 2026. Additionally, the RSI is at 45.12, indicating a lack of strong momentum. Given these factors, it may be prudent to hold rather than buy at this time, as the risks outweigh the potential rewards.